Ask AI
ProCE Banner Activity

A New Hope for Pancreatic Cancer: PARP Inhibition in Tumors With BRCA Mutations

Multimedia
Learn about PARP inhibition in BRCA-positive pancreatic cancer from 3 renowned experts.

Released: March 08, 2019

Expiration: March 06, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Learning Objectives

  • Describe the rationale for assessing BRCA1/2 and other DNA damage repair gene alterations in pancreatic cancer
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in pancreatic ductal adenocarcinoma with deficient BRCA1/2
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitors as monotherapy or in combination with other agents in pancreatic ductal adenocarcinoma

Program Director Disclosure

Program Director

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received funds for research support, consulting fees, and fees for non-CME activities from Amgen, Bayer, Caris, Celgene, Merck, Roche/Genentech, and Taiho.

Faculty Disclosure

Primary Author

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from AbbVie, Armo Biosciences, Imugene, Immuneering, and Sillajen.

Eileen O Reilly, MD

Associate Professor
Memorial Sloan Kettering Cancer Center
New York, New York

Eileen M. O’Reilly, MD, has disclosed that she has received funds for research support ActaBiologica, Agios, Array, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Lilly, MabVax, Novartis, OncoQuest, Polaris, Puma, QED, and Roche and consulting fees from 3DMedcare, Agios, AlignMed, Amgen, Antengene, Aptus, Aslan, Astellas, Astra Zeneca, Bayer, BeiGene, Bioline, Bristol-Myers Squibb, Boston Scientific, Bridgebio, CARsgen, Celgene, Casi, Cipla, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Genoscience, Gilead Sciences, Halozyme, Hengrui, Incyte, Inovio, Ipsen, Jazz, Janssen, Kyowa Kirin, LAM, Lilly, Loxo, Merck, Mina, NewLink Genetics, Novella, Onxeo, PCI Biotech, Pfizer, PharmaCyte, Pharmacyclics, Pieris, QED, RedHill, Sanofi, Servier, Silenseed, Sillajen, Sobi, Targovax, Tekmira, Twoxar, Vivus, Yakult, and Yiviva.

Eileen O Reilly, MD

Associate Attending Physician
Memorial Sloan-Kettering Cancer Center
Associate Professor
Gastrointestinal Oncology
Weill Medical College at Cornell University
New York, New York

Eileen M. O’Reilly, MD, has disclosed that she has received funds for research support ActaBiologica, Agios, Array, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Lilly, MabVax, Novartis, OncoQuest, Polaris, Puma, QED, and Roche and consulting fees from 3DMedcare, Agios, AlignMed, Amgen, Antengene, Aptus, Aslan, Astellas, Astra Zeneca, Bayer, BeiGene, Bioline, Bristol-Myers Squibb, Boston Scientific, Bridgebio, CARsgen, Celgene, Casi, Cipla, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Genoscience, Gilead Sciences, Halozyme, Hengrui, Incyte, Inovio, Ipsen, Jazz, Janssen, Kyowa Kirin, LAM, Lilly, Loxo, Merck, Mina, NewLink Genetics, Novella, Onxeo, PCI Biotech, Pfizer, PharmaCyte, Pharmacyclics, Pieris, QED, RedHill, Sanofi, Servier, Silenseed, Sillajen, Sobi, Targovax, Tekmira, Twoxar, Vivus, Yakult, and Yiviva.

Staff Disclosure

Staff

Ashley Bohn, PhD, MS, RVT

Clinical Editor

Ashley Bohn, PhD, MS, RVT, has disclosed that she has received fees for non-CME activities from Genomic Health, Lilly, and Merck.

Krista Marcello

Associate Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.

Brandon May

Editorial Contributor

Brandon May has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.